Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia.
To enhance functional outcome in schizophrenia improvement of cognitive symptoms is crucial. Using a comprehensive test battery, this follow-up examines cognitive effects in patients with recent-onset schizophrenia after a change of medication following insufficient clinical response and intolerance. After eight weeks cognitive outcomes had not improved in the patients having switched from olanzapine to ziprasidone (n=11; mean dose 136 mg) nor in those having switched from ziprasidone to olanzapine (n=10; mean 16 mg), while the symptoms of patients maintaining olanzapine (n=18; mean 10.9 mg) or ziprasidone (n=18; mean 88.9 mg) treatment had not improved further. The findings suggest that also in early-stage schizophrenia the antipsychotics tested affect cognitive symptoms similarly.